read
great
interest
articl
publish
foolad
et
al
compar
oral
aerosol
inhal
ribavirin
treatment
respiratori
syncyti
viru
rsv
infect
hematopoiet
stem
cell
transplant
hsct
recipi
popul
current
guidelin
recommend
treatment
rsv
infect
high
risk
diseas
progress
death
either
aerosol
system
ribavirin
howev
support
evid
use
ribavirin
context
larg
retrospect
limit
inhal
formul
use
oral
ribavirin
highrisk
hsct
patient
well
studi
foolad
et
al
sought
compar
rate
diseas
progress
mortal
rsvposit
hsct
recipi
treat
oral
versu
inhal
ribavirin
feel
area
signific
clinic
interest
use
inhal
ribavirin
come
consider
challeng
author
conclud
outcom
similar
treat
aerosol
oral
ribavirin
suggest
oral
ribavirin
may
suitabl
treatment
altern
patient
believ
conclus
present
studi
taken
follow
context
previou
data
recommend
use
ribavirin
hsct
patient
rsv
infect
show
signific
benefit
use
specif
highrisk
patient
unclear
whether
benefit
exist
use
low
moderaterisk
patient
studi
popul
studi
classifi
high
risk
wherea
major
patient
classifi
low
moder
risk
thu
conclus
reveal
differ
overal
mortal
rate
use
oral
inhal
ribavirin
may
primarili
due
inclus
low
moderaterisk
patient
may
benefit
ribavirin
treatment
moreov
outcom
stratifi
immunodefici
score
index
isi
found
small
proport
highrisk
patient
includ
studi
similar
mortal
rate
whether
receiv
oral
aerosol
ribavirin
note
total
number
patient
studi
classifi
high
risk
receiv
aerosol
ribavirin
receiv
oral
ribavirin
total
highrisk
patient
studi
may
underpow
detect
meaning
differ
treatment
group
subset
patient
addit
applic
isi
develop
origin
allogen
hsct
recipi
studi
popul
made
larg
proport
autolog
hsct
recipi
may
introduc
error
accuraci
risk
stratif
patient
awar
valid
isi
autolog
hsct
recipi
compliment
author
undertak
import
studi
believ
juri
still
regard
use
oral
ribavirin
clinic
practic
especi
rsvposit
hsct
recipi
high
risk
diseas
progress
andor
mortal
perhap
newer
strategi
hold
key
success
manag
diseas
